DNA Encoded Nanoparticle Vaccine Against Human Papillomavirus, and Methods of Use Thereof

Patent metadata

Field	Value
Publication number	US-2024148854-A1
Application number	US-202218552635-A
Country	US
Kind code	A1
Filing date	Mar 28, 2022
Priority date	Mar 26, 2021
Publication date	May 9, 2024
Grant date	—

Abstract

Disclosed herein are nanoparticles comprising one or more Human papillomavirus (HPV) antigen and nucleic acid molecules encoding the same. Also disclosed herein is a method of treating a HPV infection or treating or preventing a disease or disorder associated therewith in a subject in need thereof, by administering the nanoparticles, or encoding nucleic acid molecules, to the subject.

First claim

1 . A nucleic acid molecule encoding a self-assembling nanoparticle subunit polypeptide comprising:
a) a scaffold domain for nanoparticle aggregation; and b) an HPV antigen domain.

2 . The nucleic acid molecule of claim 1 , wherein the HPV antigen domain is selected from the group consisting of an HPV E1, E2, E3, E4, E5, E6, E7, L1 and L2 protein, or a fragment thereof.

3 . The nucleic acid molecule of claim 2 , wherein the HPV antigen domain comprises a fragment of an HPV E7 protein.

4 . The nucleic acid molecule of claim 3 , wherein the HPV antigen domain is selected from the group consisting of
(a) an amino acid sequence having at least about 90% identity over an entire length of SEQ ID NO:2; and (b) SEQ ID NO:2.

5 . The nucleic acid molecule of claim 4 , wherein the nucleotide sequence encoding the HPV antigen domain is selected from the group consisting of
(a) a nucleotide sequence having at least about 90% identity over an entire length of SEQ ID NO:1; and (b) SEQ ID NO:1.

6 . The nucleic acid molecule of claim 1 , wherein the nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of:
(a) a nucleotide sequence encoding and amino acid sequence having at least about 90% identity over an entire length of SEQ ID NO:4; and (b) a nucleotide sequence encoding SEQ ID NO:4.

7 . The nucleic acid molecule of claim 1 , wherein the nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of:
(a) a nucleotide sequence having at least about 90% identity over an entire length of SEQ ID NO:3; and (b) a nucleotide sequence encoding SEQ ID NO:3.

8 . The nucleic acid molecule of claim 1 , wherein the nucleic acid molecule comprises an expression vector.

9 . The nucleic acid molecule of claim 8 comprising the nucleotide sequence as set forth in SEQ ID NO:5.

10 . An immunogenic composition of comprising at least one nucleic acid molecule of claim 1 .

11 . The immunogenic composition of claim 10 , further comprising a pharmaceutically acceptable excipient.

12 . The immunogenic composition of claim 10 , further comprising an adjuvant.

13 . A peptide comprising an amino acid sequence selected from the group consisting of:
(a) a peptide comprising an amino acid sequence having at least about 90% identity over an entire length of an amino acid sequence selected from the group consisting of SEQ ID NO:4; and (b) a peptide comprising an amino acid sequence of SEQ ID NO:4.

14 . A method of inducing an immune response against human papillomavirus (HPV) in a subject in need thereof, the method comprising administering a nucleic acid molecule of claim 1 to the subject.

15 . The method of claim 14 , wherein administering includes at least one of electroporation and injection.

16 . A method of protecting a subject in need thereof from a disease or disorder associate with HPV infection, the method comprising administering a nucleic acid molecule of claim 1 to the subject.

17 . The method of the claim 16 , wherein administering includes at least one of electroporation and injection.

18 . A method of treating a subject in need thereof for an HPV infection, the method comprising administering a nucleic acid molecule of claim 1 to the subject.

19 . The method of claim 18 , wherein administering includes at least one of electroporation and injection.

Assignees

• Wistar Inst

Inventors

• Weiner David
• Liaw Kevin
• Kulp Daniel
• Tursi Nicholas
• Xu Ziyang

Classifications

• A61K39/12 Primary

  Viral antigens · CPC title

• A61K41/0047

  Sonopheresis, i.e. ultrasonically-enhanced transdermal delivery, electroporation of a pharmacologically active agent · CPC title

• A61P31/20

  for DNA viruses · CPC title

• A61P37/04

  Immunostimulants · CPC title

• C07K14/005

  from viruses · CPC title